1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
DATE OF REPORT - APRIL 7, 1999
(Date of earliest event reported)
ALKERMES CLINICAL PARTNERS, L.P.
(Exact name of Registrant as specified in its charter)
DELAWARE 0-26758 043-145043
(State of incorporation) (Commission file number) (IRS employer
identification
number)
64 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices, zip code)
AREA CODE (617) 494-0171
(Telephone number)
2
ITEM 5. OTHER INFORMATION.
As reported in the April 7, 1999 press release of Alkermes, Inc. (the
"Company"), who is developing Cereport(TM) (RMP-7) on behalf of Alkermes
Clinical Partners, L.P. pursuant to a Product Development Agreement dated as of
March 6, 1992, the Company announced its plans to discontinue study ALK01-040, a
Phase III clinical trial of Cereport and the chemotherapeutic agent carboplatin
for the treatment of newly diagnosed brain tumor patients. The entire text of
the Company's press release is incorporated by reference herein and a copy has
been filed as an exhibit to this report.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99 Press Release, dated April 7, 1999
2
3
SIGNATURES
Pursuant to requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: April 8, 1999 Alkermes Clinical Partners, L.P.
By its General Partner
Alkermes Development Corporation II
By: /s/ James M. Frates
---------------------------------
James M. Frates
Vice President, Chief Financial
Officer, Treasurer and Assistant
Secretary
3
4
Alkermes Clinical Partners, L.P.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Sequentially
Exhibit No. Exhibit Numbered Page
- ----------- ------- -------------
99 Press Release, dated April 7, 1999
4